Frequently Asked Questions

Yes. NIH proposes that the final policy supersedes the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules.

No. The draft policy includes delegated review mechanisms for many lower-risk activities.

Yes. The draft policy would require institutions to post approved IBC meeting minutes on publicly accessible websites after appropriate redactions. NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules currently require public posting of meeting minutes.

Yes. The proposal would require posting of finalized biosafety incident reports after appropriate redaction.

Potentially. Research involving biohazards conducted in animals remains subject to biosafety review. Previously exempt transgenic animals may now require IBC registration.

Yes. Certain clinical studies involving replicating, shedding, or integrating products would require IBC review.